GVAG
JAZZ icon

Great Valley Advisor Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Great Valley Advisor Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$202K Buy
+1,066
New +$186K ﹤0.01% 953
2023
Q1 		– Sell
-11,783
Closed -$1.88M – 734
2022
Q4 		$1.88M Buy
+11,783
New +$1.73M 0.1% 223

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Great Valley Advisor Group's JAZZ Position: Q1 2026 in Review

Great Valley Advisor Group opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 1,066 shares worth $202K. The stake represents ﹤0.01% of the portfolio and ranks #953 among its holdings. This is a return to the name: Great Valley Advisor Group previously reported a position in JAZZ as recently as Q4 2022.

Great Valley Advisor Group first reported a position in JAZZ in Q4 2022 and has held it in 2 quarters since. The position peaked at $1.88M in Q4 2022. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Great Valley Advisor Group held 1,066 shares of Jazz Pharmaceuticals worth $202K as of Q1 2026.
  • Jazz Pharmaceuticals was a new Great Valley Advisor Group position in Q1 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Great Valley Advisor Group's portfolio in Q1 2026, its #953 holding.
  • Great Valley Advisor Group first reported a position in Jazz Pharmaceuticals in Q4 2022 and has held it in 2 quarters since.
  • Great Valley Advisor Group's Jazz Pharmaceuticals position peaked at $1.88M in Q4 2022.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Great Valley Advisor Group's 13F filing for Q1 2026, filed 11 May 2026.